CN1245074A - 减弱阴道酸度的药剂和用途 - Google Patents
减弱阴道酸度的药剂和用途 Download PDFInfo
- Publication number
- CN1245074A CN1245074A CN98108105A CN98108105A CN1245074A CN 1245074 A CN1245074 A CN 1245074A CN 98108105 A CN98108105 A CN 98108105A CN 98108105 A CN98108105 A CN 98108105A CN 1245074 A CN1245074 A CN 1245074A
- Authority
- CN
- China
- Prior art keywords
- medicament
- vagina
- acidity
- yeast extract
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 89
- 229940079593 drug Drugs 0.000 title description 12
- 210000001215 vagina Anatomy 0.000 claims abstract description 76
- 206010046914 Vaginal infection Diseases 0.000 claims abstract description 34
- 239000003531 protein hydrolysate Substances 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 13
- 229940024606 amino acid Drugs 0.000 claims description 40
- 235000001014 amino acid Nutrition 0.000 claims description 40
- 150000001413 amino acids Chemical class 0.000 claims description 40
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 26
- 229940041514 candida albicans extract Drugs 0.000 claims description 26
- 239000012138 yeast extract Substances 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 23
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 21
- 239000000230 xanthan gum Substances 0.000 claims description 14
- 229920001285 xanthan gum Polymers 0.000 claims description 14
- 229940082509 xanthan gum Drugs 0.000 claims description 14
- 235000010493 xanthan gum Nutrition 0.000 claims description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 13
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 10
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 10
- 235000003704 aspartic acid Nutrition 0.000 claims description 10
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 10
- 235000013922 glutamic acid Nutrition 0.000 claims description 10
- 239000004220 glutamic acid Substances 0.000 claims description 10
- 229960000310 isoleucine Drugs 0.000 claims description 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 10
- 229930182817 methionine Natural products 0.000 claims description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 10
- 239000004474 valine Substances 0.000 claims description 10
- 102000015636 Oligopeptides Human genes 0.000 claims description 9
- 108010038807 Oligopeptides Proteins 0.000 claims description 9
- 229940121375 antifungal agent Drugs 0.000 claims description 9
- 230000000843 anti-fungal effect Effects 0.000 claims description 8
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 7
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- 239000001540 sodium lactate Substances 0.000 claims description 7
- 229940005581 sodium lactate Drugs 0.000 claims description 7
- 235000011088 sodium lactate Nutrition 0.000 claims description 7
- 239000001888 Peptone Substances 0.000 claims description 5
- 108010080698 Peptones Proteins 0.000 claims description 5
- 235000019319 peptone Nutrition 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 4
- 230000001186 cumulative effect Effects 0.000 claims description 2
- 238000011287 therapeutic dose Methods 0.000 claims 2
- 241000233866 Fungi Species 0.000 abstract description 7
- 201000008100 Vaginitis Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000003313 weakening effect Effects 0.000 abstract description 4
- 239000003513 alkali Substances 0.000 abstract description 3
- 206010020601 Hyperchlorhydria Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 description 16
- 239000000843 powder Substances 0.000 description 14
- 239000002253 acid Substances 0.000 description 11
- 210000003756 cervix mucus Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 8
- 229960005261 aspartic acid Drugs 0.000 description 8
- 229960002989 glutamic acid Drugs 0.000 description 8
- 235000014705 isoleucine Nutrition 0.000 description 8
- 229960003136 leucine Drugs 0.000 description 8
- 235000005772 leucine Nutrition 0.000 description 8
- 235000006109 methionine Nutrition 0.000 description 8
- 229960004452 methionine Drugs 0.000 description 8
- 229960005190 phenylalanine Drugs 0.000 description 8
- 235000008729 phenylalanine Nutrition 0.000 description 8
- 229960002429 proline Drugs 0.000 description 8
- 235000013930 proline Nutrition 0.000 description 8
- 229960004441 tyrosine Drugs 0.000 description 8
- 235000002374 tyrosine Nutrition 0.000 description 8
- 229960004295 valine Drugs 0.000 description 8
- 235000014393 valine Nutrition 0.000 description 8
- 239000003429 antifungal agent Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 5
- 208000008350 Pruritus Vulvae Diseases 0.000 description 5
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 229960004125 ketoconazole Drugs 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 4
- 229940084434 fungoid Drugs 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 208000007415 Anhedonia Diseases 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 208000001387 Causalgia Diseases 0.000 description 3
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 3
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229960003121 arginine Drugs 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 3
- 229960002433 cysteine Drugs 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 229960000988 nystatin Drugs 0.000 description 3
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 235000008521 threonine Nutrition 0.000 description 3
- 229960002898 threonine Drugs 0.000 description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 208000010484 vulvovaginitis Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 235000013527 bean curd Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960000580 terconazole Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000013464 vaginal disease Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-N sodium;hydron;carbonate Chemical compound [Na+].OC(O)=O UIIMBOGNXHQVGW-UHFFFAOYSA-N 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及以蛋白质水解物和碱为活性成分的、减弱阴道酸度的药剂,涉及特定的蛋白质水解物在制备减弱阴道酸度的药剂中的应用,还特别涉及减弱阴道酸度、治疗阴道酸度过高、以及与阴道酸度过高相关的疾病尤其是真菌性阴道炎的方法。
Description
本发明涉及以蛋白质水解物和碱为活性成分的、减弱阴道酸度的药剂,涉及特定的蛋白质水解物在制备减弱阴道酸度的药剂中的应用,还特别涉及减弱阴道酸度、治疗阴道酸度过高、以及与阴道酸度过高相关的疾病尤其是真菌性阴道炎的方法。
真菌性阴道炎是女性的三大阴道常见疾病之一(其余两个为细菌性阴道病和滴虫性阴道炎),其发病率高、根治困难。到如美国约75%以上的女性一生中至少患过一次真菌性阴道炎,约5%的成年妇女患有反复发作性、难治性真菌性阴道感染[1]。临床上主要表现为外阴瘙痒、白带增多、性交痛、排尿痛等,对女性健康与生活质量危害极大。
真菌性阴道炎的治疗,目前主要是用各种抗真菌药物直接抑制或杀死真菌,常用药物包括酮康唑、氟康唑、制霉菌素、克霉唑等等,阴道局部用药或口服给药。
但单纯抗真菌药物治疗的疗效并不理想,如常用的制霉菌素疗效一般为75-80%[1],咪唑类抗真菌药如酮康唑、曲康唑、氟康唑等的疗效好一些,但也只能达到85-90%[1]。且很多病人常常在停药后复发,或在下一个月经周期复发,极难根治。
本发明的目的是为了提供减弱阴道酸度、治疗阴道酸度过高和真菌性阴道炎的、成分简单易于制备、使用方便的药剂,以及使用该药剂治疗与阴道酸度过高或与阴道酸度过高有关的疾病尤其是真菌性阴道炎的方法。
为了提高真菌性阴道炎的疗效,本发明人首先对顽固性真菌性阴道炎的发病机理进行了深入研究。结果,令人惊奇地发现,阴道酸度过高(阴道pH<4.0)在很多顽固性真菌性外阴阴道炎的发生、发展中起着重要作用。尤其发现与现行医学观点不同,有很多被诊断为真菌性阴道炎的病例,其病征与真菌感染其实并无很强的联系,因为对其阴道分泌物进行显微镜检查并未查见真菌。进一步深入研究发现,单纯高酸度本身(阴道pH<4.0),即可刺激、损伤阴道粘膜并引起炎症,且临床表现与真菌性外阴阴道炎有很多相似之处。这些病人本质上是一种“高酸性阴道炎”,而顽固性真菌性阴道炎也总是在阴道高酸性的病理生理基础上发展而来。本发明人还发现,临床上用碳酸氢钠溶液冲洗阴道对真菌性阴道炎产生的辅助治疗作用,也并不是通常所认为的、通过碳酸氢钠溶液改变阴道微环境、抑制真菌生长起作用,而主要是碱性溶液直接缓冲阴道高酸度的结果。正是基于上述发现,本发明人认为,纠正阴道的高酸度,对于顽固性真菌性阴道炎的治疗,具有比抗真菌药物治疗更为重要的意义,这是进一步提高临床疗效的关键所在。而对部分真菌性阴道炎,甚至不必用任何抗真菌药物,只要纠正了阴道酸度过高,就可自然恢复、治愈,这在以往是不可想象的。
但碳酸氢钠溶液冲洗阴道这种治疗方法,因作用短暂,使其对阴道高酸度的疗效大受影响,加上碳酸氢钠本身并不能减少阴道中酸的生成,因而常常在用药后数小时阴道又成为高酸度状态。临床上也不能对真菌性阴道炎产生好的疗效,而只能作为一种辅助治疗方法。
为了寻求一种能有效减弱阴道酸度的药剂,本发明人进行了更深入广泛的研究。结果令人惊奇地发现,氨基酸、寡肽、多肽等蛋白质水解物、以及含氨基酸等蛋白质水解物成分较丰富的酵母浸出物,均能不同程度地改变阴道细菌的物质代谢过程,使阴道中酸性代谢产物减少、阴道的酸度减弱;与特定浓度范围的碱性物质碳酸氢钠或乳酸钠等合用时,既能直接中和阴道中的酸、又能抑制和减少阴道中酸的生成,起到协同作用。对阴道酸度过高的治疗效果,更迅速、持久,能很有效地减弱阴道酸度、升高阴道pH。基于这一发现,通过进一步的研究,本发明人完成了本发明。
本发明提供一种制备减低阴道酸度的药剂,其特征在于,按制剂总体积计,其含有总量为1.0-6.0%(W/V)的一种或多种下组蛋白质水解物:复合氨基酸、寡肽、多肽、蛋白胨、以及酵母浸出物;含有可药用的碱性物质,包括1.0-2.0%(W/V)的乳酸钠或0.8-1.5%(W/V)的碳酸氢钠;还可选择性地含有可药用的粘性基质;药剂pH值范围调至6.5<pH<8.5。
根据本发明,上述蛋白水解物可只选用一种,也可二种、多种混合使用。本发明所用的氨基酸均为L,a氨基酸。药剂中复合氨基酸是指由下列氨基酸中的全部或部分组成的氨基酸复合物:谷氨酸、天门冬氨酸、异亮氨酸、羟脯氨酸、蛋氨酸、苯丙氨酸、酪氨酸、缬氨酸、亮氨酸、脯氨酸、胱氨酸、苏氨酸、半胱氨酸、丙氨酸、甘氨酸、丝氨酸、赖氨酸、鸟氨酸、精氨酸、色氨酸、组氨酸等。其中优选的复合氨基酸由下列氨基酸组成:谷氨酸、天门冬氨酸、异亮氨酸、蛋氨酸、苯丙氨酸、酪氨酸、以及缬氨酸、亮氨酸、脯氨酸。
优选的蛋白质水解物组合为优选的复合氨基酸加酵母浸出物组成,前者包含下列种类的氨基酸:谷氨酸、天门冬氨酸、异亮氨酸、蛋氨酸、苯丙氨酸、酪氨酸、以及缬氨酸、亮氨酸、脯氨酸等组成的复合氨基酸。酵母浸出物除提供氨基酸、寡肽等外,还提供维生素等。
根据本发明,本药剂优选的蛋白质水解物总量为2.0-4.0%(W/V),其中九种优选种类氨基酸的含量各为0.8-2.5mmol/100ml,其余为酵母浸出物。
根据本发明,上述两种碱性物质可只选用一种或两种混合使用。当只选用一种时,优选的乳酸钠浓度范围为1.2-1.6%(W/V);优选的碳酸氢钠浓度范围为1.0-1.2%(W/V)。
本申请上文和下文提及的重量/体积含量(W/V)指每100毫升药剂中的克数。
本发明药剂的pH值范围为6.5<pH<8.5,优选pH值范围为7.5-8.2。药剂的pH范围可用可接受的碱或酸来调节。
根据本发明,本药剂中可包含可药用的粘性基质成分。可选用黄原胶(Xanthan Gum),浓度为范围为1.0-2.2%(W/V),优选浓度范围为1.4-1.8%(W/V)。黄原胶粘性高,且对温度、酸碱变化稳定,能使药剂中的有效成分与阴道粘膜比较均匀地接触、并停留较长时间,从而发挥调整阴道酸度的作用。
根据本发明,本制剂也可不含粘性基质成分,但需用能浸吸药液的阴道塞(棉球、纱布球、纱布条等)给药,同样能起到减弱阴道酸度的作用。
本发明药剂中的氨基酸、寡肽等蛋白质水解物组分和碱性药物组分均为活性成分,分别单独与适当的药用载体组合使用时即有效,但二者组合使用时可起协同作用、增强效果。
本发明药剂中还可以含有有效量的抗真菌剂,用于抑制、杀灭真菌,增强对真菌性阴道炎的治疗效果。抗真菌药物的例子有酮康唑、曲康唑、伊曲康唑、氟康唑等。
本发明药剂可按本领域技术人员已知的方法制备。
当蛋白质水解物组分选用氨基酸、酵母浸出粉时,将氨基酸组分、酵母浸出粉组分与粘性辅料成分混匀,加蒸馏水、搅拌使蛋白质水解物组分溶解、粘性辅料成分溶涨呈均匀粘性胶状。加入碱性组分,调pH值,再经灭菌即可。灭菌可选用116摄氏度15-20分钟高压灭菌,也可采用间歇灭菌法。
本发明制剂也可将蛋白质水解物组分和碱性物质组分溶于水制成溶液形式,在病人使用前用该溶液浸泡阴道塞即可。
本发明还涉及一种或多种选自下列的蛋白质水解物在制备减低阴道酸度的制剂中的应用:复合氨基酸、寡肽、多肽、蛋白胨、以及酵母浸出物。
根据本发明,上述蛋白水解物可只选用一种,也可二种、多种混合使用。本发明所用的氨基酸均为L,a氨基酸。药剂中复合氨基酸是指由下列氨基酸中的全部或部分组成的氨基酸复合物:谷氨酸、天门冬氨酸、异亮氨酸、羟脯氨酸、蛋氨酸、苯丙氨酸、酪氨酸、缬氨酸、亮氨酸、脯氨酸、胱氨酸、苏氨酸、半胱氨酸、丙氨酸、甘氨酸、丝氨酸、赖氨酸、鸟氨酸、精氨酸、色氨酸、组氨酸等。其中优选种类的氨基酸为谷氨酸、天门冬氨酸、异亮氨酸、蛋氨酸、苯丙氨酸、酪氨酸、以及缬氨酸、亮氨酸、脯氨酸。
优选的蛋白质水解物组合为酵母浸出物加下列优选种类的氨基酸组成:谷氨酸、天门冬氨酸、异亮氨酸、蛋氨酸、苯丙氨酸、酪氨酸、以及缬氨酸、亮氨酸、脯氨酸。酵母浸出物除提供氨基酸、寡肽等外,还提供维生素等。
本发明制剂可用于减弱阴道的酸度,用于治疗阴道酸度过高(pH<4.0),以及与阴道酸度过高相关的阴道疾病,如真菌性阴道炎。
经体内体外实验证明,本发明的制剂具有很强的减弱阴道酸度的作用,可用于治疗阴道酸度过高及相关疾病。
因此,本发明还涉及一种减弱阴道酸度、治疗阴道酸度过高、以及与阴道酸度过高相关的疾病,特别是真菌性阴道炎的方法,其中包括给予有此需要的患者以治疗有效量的上述本发明药剂。
在本发明的方法中,可以给予患者仅含本发明的蛋白水解物和碱性物质作为活性成分的药剂,也可给予含有蛋白水解物、碱性物质和抗真菌剂的本发明药剂,或者仅将含本发明的蛋白水解物与碱性物质的药剂与适当抗真菌剂结合使用。在后一种情况下,本发明药剂可与抗真菌剂同时给药,或先后给药,对给药顺序没有严格要求,只要在第一种药剂的有效作用期间给予第二种药剂即可。
本发明药剂和本发明治疗方法中的给药方法是阴道内局部给药,对于含有粘性基质的本发明药剂,可以直接施用于阴道内,对于不含有粘性基质的本发明药剂,可用于浸泡阴道塞,然后用本发明药剂浸泡的阴道塞用于患者阴道内。
本药剂使用后可使患者的临床症状迅速缓解,阴道pH升高至4.0以上,阴道内真菌的量减少。
对于阴道酸度过高的病例,给予本发明药剂3-5ml,每日1-3次,至症状减轻、阴道pH升至4.4-4.6时减量维持给药或停药;对于典型真菌性阴道炎病例、尤其是顽固性反复发作性真菌性阴道炎,用含抗真菌剂的本发明药剂3-5ml,每日1-3次,至症状减轻、阴道pH升至4.4-4.6时减量维持给药或停药。
以下参照下列实验实施例说明本发明药剂或方法的有效性。
试验实例1
典型病例研究
病例1,女性,32岁。阴部瘙痒伴疼痛2年,以月经前为重,来月经后减轻。多次就诊为“真菌性阴道炎”,经抗真菌治疗、及阴道冲洗后好转,但停药后又复发。经本发明人取阴道分泌物检查,测pH<3.8,涂片染色镜检查见真菌孢子。诊断为“阴道酸度过高伴真菌感染”。给予含3.0%复合氨基酸、1.0%酵母浸出粉、1.0%碳酸氢钠、1.6%黄原胶的本发明药剂,每次3ml,每日两次。用药一天症状显著减轻,分泌物减少,用药三天外阴瘙痒消失,测阴道分泌物pH为4.4,涂片染色检查真菌孢子未查见,遂停药。但月经后2周阴道pH又<4.0,但症状显著较以前减轻,再给本发明药剂1ml、每日两次治疗,使症状消失。如此治疗3月后未再复发。
试验实例2
病例2,女性30岁。外阴瘙痒、白带增多伴性交痛1年余。患者于1年前无明显诱因出现外阴瘙痒、灼痛,月经前为著,严重时坐立不安。伴白带增多、性交痛。多次在就诊均为“真菌性阴道炎”。先后用制霉菌素泡腾片、达克宁栓(酮康唑)局部用药以及口服氟康唑等,用药时症状明显减轻,但停药后或者月经后病情又逐渐出现、加重。经本发明人取阴道分泌物检查,测pH<3.8,涂片染色镜检未见真菌孢子与真菌菌丝,诊断为“高酸性阴道炎”。给予含5.0%胰蛋白胨与1.6%黄原胶的本发明药剂,每次4ml,每日两次,用药一天后外阴瘙痒即显著减轻,白带开始减少,测阴道分泌物pH值为4.0。继续用药3天,测阴道分泌物pH为4.4。遂减量维持,2月后彻底治愈,未再复发。
典型病例研究
试验实例3
病例3,女性28岁。外阴瘙痒、灼痛、白带增多伴有豆腐渣样凝块半年多。曾多次诊断为“真菌性阴道炎”,抗真菌药物治疗可控制病情,但不能停药。经本发明人检查,其阴道分泌物pH<3.8,阴道分泌物中查见大量真菌菌丝。给予含3.0%酵母浸出粉、1.5%乳酸钠、2.0%酮康唑、1.8%黄原胶的本发明药剂,每次3ml,每日两次。用药二天,瘙痒、灼痛显著减轻,白带减少、豆腐渣样凝块消失。查阴道酸度减弱、分泌物pH4.0,未查见真菌,继续用药至阴道分泌物pH至4.4停药。
试验实例4
本发明药剂的体外实验
实验方法:
(1)准备药剂:分别选用酵母浸出粉、黄原胶,按照前述制备方法,准
备下述药剂。为了能考察蛋白质水解物组分单独作用对阴道细菌产
酸的影响,本实验药剂中未加入乳酸钠或碳酸氢钠。在本实验药剂
中另添加1%的麦芽糖作为碳源。
A.酵母浸出粉1.0%(W/V)、麦芽糖1%(W/V)、黄原胶1.6%(W/V),pH6.7
B.酵母浸出粉5.0%(W/V)、麦芽糖1%(W/V)、黄原胶1.6%(W/V),pH6.7
上述药剂经灭菌处理后分装试管,每管5ml,备用。
(2)准备标本液:取阴道分泌物pH值<4.0的患者的阴道拭子,立即洗脱
于2ml灭菌大豆胰酶蛋白胨培养液中洗脱成混悬液,即为标本液。该
分泌物经涂片染色镜检,以革兰氏阳性杆菌为主,阳性球菌、阴性杆
菌极少。
(3)立即接种上述刚准备好的标本液于药剂管中,每管接种10ul,混
匀,置37摄氏度厌氧培养,分别于10小时、24小时测培养物pH
值,并取培养物涂片染色观察。
结果:如表所示,含酵母浸出粉的量为1.0%的本发明药剂对阴道菌的产酸似无明显抑制作用,培养10-24小时培养物pH值下降至4.1;而含酵母浸出粉的量为5.0%的本发明药剂对阴道菌产酸则有明显抑制作用,培养10-24小时培养物pH值为5.1。药剂中酵母 标本中 药剂pH 培养10小时 培养24小时浸出物(%) 细菌 pH 细菌 pH 细菌1% G+b 6.7 6.5 G+b 4.1 G-b,G+c5% G+b 6.7 6.5 G-b 5.1 G+c,G-b
结论:酵母粉含大量氨基酸、寡肽等蛋白质水解物、维生素等。本实验中含较高酵母浸出物含量的本发明药剂对阴道革兰氏阳性杆菌产酸甚至生长都有抑制作用,证明蛋白质水解物单独作用,即可减少阴道细菌产酸。
本发明与背景技术相比较的优越性:
本发明依据理论上对单纯阴道酸度过高本身即可引起“高酸性阴道炎”并可诱发真菌性阴道炎这一重要发现,对真菌性阴道炎、高酸性阴道炎提出了全新的治疗概念。与现有的治疗真菌性阴道炎的治疗手段比较,本发明药剂的疗效和根治率提高,甚至用不含任何抗真菌药物的本发明药剂,也可治愈部分阴道真菌感染,这对于现有技术来讲是很难想象的。
现有技术中也使用碳酸氢钠溶液作为治疗真菌性外阴阴道炎的辅助治疗药物。但单纯的碳酸氢钠溶液冲洗阴道作用时间短暂,且不能减少阴道中酸的生成,对阴道高酸度的疗效有限、更不能单独用于治疗真菌性阴道炎。本发明药剂和治疗方法则既能直接中和阴道的高酸、又能减少阴道中酸的生成,因而提高了疗效和治愈率。
药剂实施例
实施例1
将3.0g酵母浸出粉、1.0g碳酸氢钠、1.6g黄原胶混匀,加入100蒸馏水搅拌,使酵母粉和碳酸氢钠溶解、黄原胶溶胀呈均匀粘性胶状,经灭菌即可。
实施例2
按下述配比称取原料,基本按实施例1的方法制备了100药剂。
氨基酸组分:谷氨酸0.5mmol,天门冬氨酸0.5mmol,异亮氨酸0.5mmol,羟脯氨酸0.5mmol,蛋氨酸0.5mmol,苯丙氨酸0.5mmol,酪氨酸0.5mmol,缬氨酸0.5mmol,亮氨酸0.5mmol,脯氨酸0.5mmol,胱氨酸0.5mmol,苏氨酸0.5mmol,半胱氨酸0.5mmol,丙氨酸0.5mmol,甘氨酸0.5mmol,丝氨酸0.5mmol,赖氨酸0.5mmol,鸟氨酸0.5mmol,精氨酸0.5mmol,色氨酸0.5mmol,组氨酸0.5mmol;酵母浸出粉1.0%(W/V);碳酸氢钠1.0%(W/V);黄原胶1.6%(W/V);水足量。调药剂pH8.3。
实施例3
按下述配比称取原料,基本按实施例1的方法制备了100药剂。
氨基酸组分:谷氨酸1.0mmol,天门冬氨酸1.0mmol,异亮氨酸1.0mmol,蛋氨酸1.0mmol,苯丙氨酸1.0mmol,酪氨酸1.0mmol,缬氨酸1.0mmol,亮氨酸1.0mmol,脯氨酸1.0mmol;2.0%(W/V)酵母浸出粉;1.5%乳酸钠(W/V);1.5%(W/V)黄原胶;水足量。药剂pH调至6.5
参考文献
1.JACK D.SOBEL.MD.Candidal Vulvovaginitis. Clinical Obstetrics
and Gynecology 1993.Vol.36(1):153-165.
Claims (17)
1.减弱阴道酸度的药剂,其特征在于,按药剂的总体积计,其含有1-6%(W/V)的一种或多种选自下组的蛋白质水解物:复合氨基酸、寡肽、多肽、蛋白胨,以及酵母浸出物;含有可药用的碱性物质,0.8-1.5%(W/V)碳酸氢钠或1.0-2.0%(W/V)乳酸钠;还可选择性地含有可药用的粘性基质;其pH值调至6.5-8.5范围内。
2.根据权利要求1的药剂,其中所述复合氨基酸主要由下列氨基酸组成:谷氨酸、天门冬氨酸、异亮氨酸、蛋氨酸、苯丙氨酸、酪氨酸、缬氨酸、亮氨酸、脯氨酸。
3.根据权利要求1-2的药剂,其中所述蛋白质水解物由权利要求2中的复合氨基酸和酵母浸出物组成。
4.根据权利要求1-3的药剂,其中蛋白质水解物的含量为1-6%(W/V)。
5.根据权利要求4的药剂,其中蛋白质水解物的含量为2-4%(W/V)。
6.根据权利要求3-5的药剂,其中蛋白质水解物中的9种氨基酸的含量分别为0.8-2.5mmol/100ml,其余为酵母浸出物。
7.根据权利要求1的药剂,其中所述碱性物质为碳酸氢钠。
8.根据权利要求1的药剂,其中含有1.0-2.2%(W/V)的黄原胶。
9.根据权利要求1的药剂,其中不含粘性基质以浸泡阴道塞。
10.根据权利要求1的药剂,其中还含有有效量的抗真菌剂。
11.一种或多种选自下组的蛋白质水解物作为活性成分在制备减弱阴道酸度的药物中的用途:复合氨基酸、寡肽、多肽、蛋白胨,以及酵母浸出物。
12.根据权利要求11的用途,其中所述复合氨基酸由主要下列氨基酸组成:谷氨酸、天门冬氨酸、异亮氨酸、蛋氨酸、苯丙氨酸、酪氨酸、缬氨酸、亮氨酸、脯氨酸。
13.根据权利要求11-12的用途,其中所述蛋白质水解物由权利要求12中的复合氨基酸和酵母浸出物组成。
14.根据权利要求11-13之一的用途,其中所述药物是用于治疗阴道酸度过高的药物。
15.根据权利要求11-13之一的用途,其中所述药物是用于治疗真菌性阴道炎的药物。
16.一种减弱阴道酸度的方法,其中给予有此需要的主体以有效治疗量的权利要求1-10任一项的药剂。
17.一种治疗真菌性阴道炎的方法,其中给予有此需要的主体以有效治疗量的权利要求1-10任一项的药剂。
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98108105A CN1245074A (zh) | 1998-04-26 | 1998-04-26 | 减弱阴道酸度的药剂和用途 |
| AU35935/99A AU3593599A (en) | 1998-04-26 | 1999-04-26 | Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof |
| CNB2004100312546A CN1308033C (zh) | 1998-04-26 | 1999-04-26 | 减弱阴道酸度及治疗阴道炎的药物及其用途 |
| US09/674,062 US6770306B1 (en) | 1998-04-26 | 1999-04-26 | Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof |
| CNB998055026A CN1154487C (zh) | 1998-04-26 | 1999-04-26 | 减弱阴道酸度及治疗阴道炎的药物及其用途 |
| PCT/CN1999/000059 WO1999055325A1 (en) | 1998-04-26 | 1999-04-26 | Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof |
| US10/798,072 US7262170B2 (en) | 1998-04-26 | 2004-03-11 | Pharmaceutical composition for reducing vaginal acidity and treatment of vaginitis, and the use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98108105A CN1245074A (zh) | 1998-04-26 | 1998-04-26 | 减弱阴道酸度的药剂和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1245074A true CN1245074A (zh) | 2000-02-23 |
Family
ID=5219502
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98108105A Pending CN1245074A (zh) | 1998-04-26 | 1998-04-26 | 减弱阴道酸度的药剂和用途 |
| CNB998055026A Expired - Fee Related CN1154487C (zh) | 1998-04-26 | 1999-04-26 | 减弱阴道酸度及治疗阴道炎的药物及其用途 |
| CNB2004100312546A Expired - Fee Related CN1308033C (zh) | 1998-04-26 | 1999-04-26 | 减弱阴道酸度及治疗阴道炎的药物及其用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB998055026A Expired - Fee Related CN1154487C (zh) | 1998-04-26 | 1999-04-26 | 减弱阴道酸度及治疗阴道炎的药物及其用途 |
| CNB2004100312546A Expired - Fee Related CN1308033C (zh) | 1998-04-26 | 1999-04-26 | 减弱阴道酸度及治疗阴道炎的药物及其用途 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US6770306B1 (zh) |
| CN (3) | CN1245074A (zh) |
| AU (1) | AU3593599A (zh) |
| WO (1) | WO1999055325A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102470117A (zh) * | 2009-10-08 | 2012-05-23 | 曾忠铭 | 一种以苯甲酸和有机酸防腐剂相联合作为有效成分的组合物及其用途 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7262170B2 (en) * | 1998-04-26 | 2007-08-28 | Zhongming Zeng | Pharmaceutical composition for reducing vaginal acidity and treatment of vaginitis, and the use thereof |
| US7311925B2 (en) * | 2001-01-22 | 2007-12-25 | Michael A Zasloff | Methods and compositions for blocking microbial adherence to eukaryotic cells |
| US7508479B2 (en) | 2001-11-15 | 2009-03-24 | Samsung Electronics Co., Ltd. | Liquid crystal display |
| EP1500394A1 (en) * | 2003-07-22 | 2005-01-26 | Polichem S.A. | Pharmaceutical compositions comprising ascorbic acid or the treatment of fungal superinfections and fungal recurrences |
| EP2272523A1 (en) * | 2004-09-01 | 2011-01-12 | Chitra Vasant Savangikar | Compounds, compositions, formulations and process for preparation thereof and method of treatment and management of acidity and related disorders |
| US20070141177A1 (en) * | 2005-12-16 | 2007-06-21 | Max Rosenberg | Method for enhancing fertility |
| US7470434B1 (en) * | 2007-07-28 | 2008-12-30 | Michael A Zasloff | Methods and compositions for blocking microbial adherence to eukaryotic cells |
| US9314524B2 (en) * | 2007-12-31 | 2016-04-19 | Calla Therapeutics Llc | Topical formulations of Flucytosine |
| CA2897038C (en) | 2014-07-14 | 2016-10-04 | Novicol International Holding Inc. | Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof |
| CN111848740B (zh) * | 2020-08-04 | 2023-03-24 | 南京市妇幼保健院 | 一种阴道分泌源性多肽及其在抑制白色念珠菌感染中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607570D0 (en) | 1986-03-26 | 1986-04-30 | Euro Celtique Sa | Vaginal pharmaceutical preparation |
| DE3631206A1 (de) * | 1986-04-10 | 1987-10-15 | Salgad Int Ltd | Drehlagerung des sattels mit einer ein gschuetzrohr, vornehmlich ein werferrohr, aufnehmenden wiege |
| US4937234A (en) * | 1988-08-10 | 1990-06-26 | Fahim Mostafa S | Minerals in bioavailable form |
| JPH02124087A (ja) * | 1988-11-02 | 1990-05-11 | Res Assoc Util Of Light Oil | シユードモナス属細菌の培養方法 |
| US5573765A (en) * | 1991-02-19 | 1996-11-12 | Mark S. Reinhard | Composition and method for treatment of vaginal yeast infections |
| WO1995001432A1 (en) * | 1993-06-29 | 1995-01-12 | Seikagaku Kogyo Kabushiki Kaisha | Novel polypeptide and dna coding for the same |
| EP0839156A1 (en) * | 1995-07-20 | 1998-05-06 | Xoma Corporation | Anti-fungal peptides |
-
1998
- 1998-04-26 CN CN98108105A patent/CN1245074A/zh active Pending
-
1999
- 1999-04-26 US US09/674,062 patent/US6770306B1/en not_active Expired - Fee Related
- 1999-04-26 WO PCT/CN1999/000059 patent/WO1999055325A1/zh not_active Ceased
- 1999-04-26 CN CNB998055026A patent/CN1154487C/zh not_active Expired - Fee Related
- 1999-04-26 CN CNB2004100312546A patent/CN1308033C/zh not_active Expired - Fee Related
- 1999-04-26 AU AU35935/99A patent/AU3593599A/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102470117A (zh) * | 2009-10-08 | 2012-05-23 | 曾忠铭 | 一种以苯甲酸和有机酸防腐剂相联合作为有效成分的组合物及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999055325A1 (en) | 1999-11-04 |
| CN1154487C (zh) | 2004-06-23 |
| US6770306B1 (en) | 2004-08-03 |
| CN1308033C (zh) | 2007-04-04 |
| CN1299275A (zh) | 2001-06-13 |
| AU3593599A (en) | 1999-11-16 |
| CN1552438A (zh) | 2004-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1072268B1 (en) | Pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof | |
| US20030017207A1 (en) | Compositions and methods for treating vulvovaginitis and vaginosis | |
| CA3078631A1 (en) | Methods and compositions for topical delivery | |
| CN102470117B (zh) | 一种以苯甲酸和有机酸防腐剂相联合作为有效成分的组合物及其用途 | |
| CN1223546A (zh) | 单纯性疱疹病毒和其它感染性疾病的抗微生物疗法 | |
| CN1245074A (zh) | 减弱阴道酸度的药剂和用途 | |
| CN1141929C (zh) | 药物制剂 | |
| CN1312080A (zh) | 含有脂肪酸的组合物 | |
| US6964949B2 (en) | Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof | |
| US7262170B2 (en) | Pharmaceutical composition for reducing vaginal acidity and treatment of vaginitis, and the use thereof | |
| JPH01261334A (ja) | アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法 | |
| US20030064103A1 (en) | Compositions and methods for treating vulvovaginitis and vaginosis | |
| CN101156849B (zh) | 一种促牙周再生的苯妥英钠缓释凝胶及其制备方法与应用 | |
| Jacobs | Treatment of fungal skin infections: state of the art | |
| CN1246333A (zh) | 聚羧酸聚合物在治疗阴道感染上的用途 | |
| CN1063632C (zh) | 一种治疗皮肤病的外用搽剂 | |
| CN1224390C (zh) | 含吡咯并喹啉醌的治疗和预防脂肪肝的药物组合物 | |
| CN1264581A (zh) | 减弱阴道酸度的药物和用途 | |
| CN112535690A (zh) | 供氧与杀菌二合一的三氧眼部清洗护理洗剂 | |
| CN1850100A (zh) | 一种用于治疗阴道疾病的药物组合物 | |
| RU2290188C2 (ru) | Способ лечения воспалительных и реактивно-дистрофических заболеваний больших слюнных желез | |
| CN120437267A (zh) | 沙丁鱼肽组合物在制备防治唇炎的药物中的新用途 | |
| JPH10175860A5 (zh) | ||
| KR20040012779A (ko) | 외음부질염 및 질증을 치료하기 위한 항진균제를 포함하는조성물 | |
| CN1839882A (zh) | 一种治疗脚癣和体癣的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |